Enveric Biosciences (ENVB) Competitors $0.33 -0.02 (-5.74%) (As of 02:50 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ENVB vs. NRSN, NLSP, SNSE, TLPH, APLM, EGRX, CSCI, INDP, CDT, and KPRXShould you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include NeuroSense Therapeutics (NRSN), NLS Pharmaceutics (NLSP), Sensei Biotherapeutics (SNSE), Talphera (TLPH), Apollomics (APLM), Eagle Pharmaceuticals (EGRX), COSCIENS Biopharma (CSCI), Indaptus Therapeutics (INDP), Conduit Pharmaceuticals (CDT), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical preparations" industry. Enveric Biosciences vs. NeuroSense Therapeutics NLS Pharmaceutics Sensei Biotherapeutics Talphera Apollomics Eagle Pharmaceuticals COSCIENS Biopharma Indaptus Therapeutics Conduit Pharmaceuticals Kiora Pharmaceuticals Enveric Biosciences (NASDAQ:ENVB) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, community ranking, earnings, valuation, institutional ownership and media sentiment. Do analysts recommend ENVB or NRSN? Enveric Biosciences currently has a consensus price target of $10.00, suggesting a potential upside of 2,932.14%. Given Enveric Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Enveric Biosciences is more favorable than NeuroSense Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NeuroSense Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, ENVB or NRSN? Enveric Biosciences has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Does the MarketBeat Community favor ENVB or NRSN? Enveric Biosciences received 3 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 100.00% of users gave NeuroSense Therapeutics an outperform vote while only 55.56% of users gave Enveric Biosciences an outperform vote. CompanyUnderperformOutperformEnveric BiosciencesOutperform Votes555.56% Underperform Votes444.44% NeuroSense TherapeuticsOutperform Votes2100.00% Underperform VotesNo Votes Does the media refer more to ENVB or NRSN? In the previous week, Enveric Biosciences had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 2 mentions for Enveric Biosciences and 1 mentions for NeuroSense Therapeutics. Enveric Biosciences' average media sentiment score of 0.79 beat NeuroSense Therapeutics' score of 0.64 indicating that Enveric Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enveric Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroSense Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ENVB or NRSN? 13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 1.2% of Enveric Biosciences shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ENVB or NRSN more profitable? NeuroSense Therapeutics' return on equity of 0.00% beat Enveric Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Enveric BiosciencesN/A -221.54% -164.32% NeuroSense Therapeutics N/A N/A -286.31% Which has stronger earnings & valuation, ENVB or NRSN? NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnveric BiosciencesN/AN/A-$17.29M-$2.56-0.13NeuroSense TherapeuticsN/AN/A-$11.28M-$0.85-1.12 SummaryEnveric Biosciences beats NeuroSense Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENVB vs. The Competition Export to ExcelMetricEnveric BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.18M$6.49B$5.09B$8.79BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-0.135.3293.0914.02Price / SalesN/A370.921,220.6787.41Price / CashN/A52.5939.4936.27Price / Book0.8010.236.936.33Net Income-$17.29M$153.22M$118.83M$225.71M7 Day Performance-19.37%-1.99%-1.74%-0.58%1 Month Performance-40.50%-7.51%-3.60%1.49%1 Year Performance-77.14%31.02%31.91%27.23% Enveric Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENVBEnveric Biosciences2.4612 of 5 stars$0.33-5.7%$10.00+2,932.1%-76.0%$3.28MN/A-0.137Gap DownNRSNNeuroSense Therapeutics0.6395 of 5 stars$0.95-3.6%N/A+92.7%$13.05MN/A0.0018Upcoming EarningsNLSPNLS Pharmaceutics1.2189 of 5 stars$3.31+0.6%N/A+623.1%$12.64MN/A0.006SNSESensei Biotherapeutics4.8056 of 5 stars$0.48-3.9%$4.33+805.6%-20.0%$12.03MN/A0.0040News CoverageTLPHTalphera2.6915 of 5 stars$0.68-4.3%$4.50+565.6%N/A$11.51M$650,000.000.0019Gap UpAPLMApollomics2.7525 of 5 stars$0.10-31.8%$2.00+1,856.9%-81.3%$11.11M$1.22M0.0045Gap DownEGRXEagle Pharmaceuticals1.1175 of 5 stars$0.85+30.3%N/A-92.5%$11.04M$316.61M0.00134Analyst ForecastGap UpCSCICOSCIENS BiopharmaN/A$2.88-3.4%N/AN/A$10.83M$4.50M0.00N/AGap DownINDPIndaptus Therapeutics2.7304 of 5 stars$1.04-1.9%$8.50+717.3%-48.7%$10.61MN/A0.006CDTConduit PharmaceuticalsN/A$0.11+19.2%N/A-92.8%$10.56MN/A0.003News CoverageGap UpHigh Trading VolumeKPRXKiora Pharmaceuticals3.0135 of 5 stars$3.38-1.2%$10.00+195.9%-32.4%$10.14MN/A0.0010 Related Companies and Tools Related Companies NRSN Alternatives NLSP Alternatives SNSE Alternatives TLPH Alternatives APLM Alternatives EGRX Alternatives CSCI Alternatives INDP Alternatives CDT Alternatives KPRX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENVB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
